185 related articles for article (PubMed ID: 33979958)
21. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
22. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
[TBL] [Abstract][Full Text] [Related]
23. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
Mo Y; Pan Y; Zhang B; Zhang J; Su Y; Liu Z; Luo M; Qin G; Kong X; Zhang R; Pan Y; Liang Y; Wang D; Wei Y; Chen H; Jiang W
Front Immunol; 2023; 14():1298418. PubMed ID: 38239359
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma.
Zhu Y; Feng B; Mei L; Sun R; Guo C; Zhu J
J BUON; 2019; 24(2):608-614. PubMed ID: 31128013
[TBL] [Abstract][Full Text] [Related]
25. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
Ma N; Qiao H; Tao H; Gan X; Shan Z; Chen X; Zhou X
Clin Res Hepatol Gastroenterol; 2022; 46(7):101962. PubMed ID: 35636681
[TBL] [Abstract][Full Text] [Related]
26. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
27. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.
Zhang TQ; Geng ZJ; Zuo MX; Li JB; Huang JH; Huang ZL; Wu PH; Gu YK
Signal Transduct Target Ther; 2023 Oct; 8(1):413. PubMed ID: 37884523
[TBL] [Abstract][Full Text] [Related]
28. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
[No Abstract] [Full Text] [Related]
29. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Hu Y; Zhou M; Tang J; Li S; Liu H; Hu J; Ma H; Liu J; Qin T; Yu X; Chen Y; Peng J; Zou Y; Zhang T; Xue J
Clin Cancer Res; 2023 Oct; 29(20):4088-4097. PubMed ID: 37556120
[TBL] [Abstract][Full Text] [Related]
30. Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.
Chen D; Wang Y; Chen X; Kang M; Zhu L
Sci Rep; 2023 Aug; 13(1):13285. PubMed ID: 37587189
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study.
Yu WC; Zhang KZ; Chen SG; Liu WF
Medicine (Baltimore); 2018 Jan; 97(3):e9704. PubMed ID: 29505026
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
Li C; Yu F; Xu W
J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis.
Chen M; Li Y; Cheng M
BMC Gastroenterol; 2024 Jan; 24(1):55. PubMed ID: 38297195
[TBL] [Abstract][Full Text] [Related]
34. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.
Huang J; Liang R; Lu C; Lu L; Li S; Tang M; Huang X; Huang S; Mai R; Gao X; Li S; Zeng C; Lin Y; Ye J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686291
[TBL] [Abstract][Full Text] [Related]
35. Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.
Liu XL; Li XZ; Chu YF; Liu F; Tian H
Front Oncol; 2024; 14():1280805. PubMed ID: 38601767
[TBL] [Abstract][Full Text] [Related]
36. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.
Qiu H; Ke S; Cai G; Wu Y; Wang J; Shi W; Chen J; Peng J; Yu B; Chen Y
Cancer Med; 2023 Jan; 12(1):213-222. PubMed ID: 35633045
[TBL] [Abstract][Full Text] [Related]
37. Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma.
Li Y; Li HL; Hu HT; Shao SS; Chen CS; Guo CY; Zhao Y; Yao QJ
J Cancer Res Ther; 2021 Dec; 17(7):1718-1724. PubMed ID: 35381744
[TBL] [Abstract][Full Text] [Related]
38. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
39. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX; Cui TY; Yang XD; Wang GQ; Jiang QS; Sun H; Jiang NY; Yong XM; Shi CB; Ding YB; Chen XF; Fang YY
Onco Targets Ther; 2021; 14():4859-4865. PubMed ID: 34584426
[TBL] [Abstract][Full Text] [Related]
40. Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study.
Wu K; Li Y; Li Z; Zhou Z; Ge X; Li Y; Han X; Chen P; Ren K
Front Oncol; 2023; 13():1143578. PubMed ID: 37746269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]